Review on pharmacokinetics and pharmacodynamics and the aging kidney

Clinical Journal of the American Society of Nephrology

Volumn 5, Issue 2, 2010, Pages 314-327

  Aymanns, Christian ^a   Keller, Frieder ^b   Maus, Sebastian ^b   Hartmann, Bertram ^b   Czock, David ^c  

^a UNIVERSITY OF GREIFSWALD   (Germany)

^b UNIVERSITY OF ULM   (Germany)

^c UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; AMITRIPTYLINE; AMLODIPINE; ARGATROBAN; CALCIUM; CITALOPRAM; CLOMETHIAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; DOCETAXEL; EDROPHONIUM; ENOXAPARIN; EPTIFIBATIDE; FAMOTIDINE; LABETALOL; LEVODOPA; LEVOFLOXACIN; LIDOCAINE; LINEZOLID; LITHIUM; PARACETAMOL; PROPRANOLOL; RABEPRAZOLE; ROPINIROLE; THEOPHYLLINE; TIROFIBAN; UNINDEXED DRUG; VANCOMYCIN; VERAPAMIL; VILDAGLIPTIN;

AGING; DOSE RESPONSE; DRUG EXCRETION; DRUG HALF LIFE; HUMAN; KIDNEY; KIDNEY FUNCTION; KINETICS; PR INTERVAL; PREDICTION; REVIEW; SIDE EFFECT;

AGE FACTORS; AGED; AGING; DATABASES AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY; KIDNEY DISEASES; MODELS, BIOLOGICAL; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; SEVERITY OF ILLNESS INDEX;

EID: 77749334639     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.03960609     Document Type: Review

References (91)

1. Shi S, Mörike K, Klotz U: The clinical implications of ageing for rational drug therapy. Eur J Clin Pharmacol 64: 183-199, 2008
2. Turnheim K: Pharmacokinetic dosage guidelines for elderly subjects. Expert Opin Drug Metab Toxicol 1: 33-48, 2005
3. Gurwitz JH, Avorn J: The ambiguous relation between aging and adverse drug reactions. Ann Intern Med 114: 956-966, 1991
4. Balducci L, Extermann M: Management of cancer in the older person: A practical approach. Oncologist 5: 224-237, 2000
5. Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, Seeman T, Tracy R, Kop WJ, Burke G, McBurnie MA, Cardiovascular Health Study Collaborative Research Group: Frailty in older adults: Evidence for a phenotype. J Gerontol A Biol Sci Med Sci 56: M146-M156, 2001
6. Hanlon JT, Aspinall SL, Semla TP, Weisbord SD, Fried LF, Good CB, Fine MJ, Stone RA, Pugh MJ, Rossi MI, Handler SM: Consensus guidelines for oral dosing of primarily renally cleared medications in older adults. J Am Geriatr Soc 57: 335-340, 2009
7. Young A: Ageing and physiological functions. Philos Trans R Soc Lond B Biol Sci 352: 1837-1843, 1997
8. Mühlberg W, Platt D: Age-dependent changes of the kidneys: Pharmacological implications. Gerontology 45: 243-253, 1999
9. Fülöp T Jr, Wórum I, Csongor J, Fó ris G, Leövey A: Body composition in elderly people: I. Determination of body composition by multiisotope method and the elimination kinetics of these isotopes in healthy elderly subjects. Gerontology 31: 6-14, 1985
10. McLean AJ, Le Couteur DG: Aging biology and geriatric clinical pharmacology. Pharmacol Rev 56: 163-184, 2004
11. Ginsberg G, Hattis D, Russ A, Sonawane B: Pharmacokinetic and pharmacodynamic factors that can affect sensitivity to neurotoxic sequelae in elderly individuals. Environ Health Perspect 113: 1243-1249, 2005
12. Zoli M, Magalotti D, Bianchi G, Gueli C, Orlandini C, Grimaldi M, Marchesini G: Total and functional hepatic blood flow decrease in parallel with ageing. Age Ageing 28: 29-33, 1999
13. Wynne HA, Cope LH, Mutch E, Rawlins MD, Woodhouse KW, James OF: The effect of age upon liver volume and apparent liver blood flow in healthy man. Hepatology 9: 297-301, 1989
14. Gourtsoyiannis N, Prassopoulos P, Cavouras D, Pantelidis N: The thickness of the renal parenchyma decreases with age: A CT study of 360 patients. AJR Am J Roentgenol 155: 541-544, 1990
15. Fliser D, Zeier M, Nowack R, Ritz E: Renal functional reserve in healthy elderly subjects. J Am Soc Nephrol 3: 1371-1377, 1993
16. Fliser D, Franek E, Joest M, Block S, Mutschler E, Ritz E: Renal function in the elderly: Impact of hypertension and cardiac function. Kidney Int 51: 1196-1204, 1997
17. Fuiano G, Sund S, Mazza G, Rosa M, Caglioti A, Gallo G, Natale G, Andreucci M, Memoli B, De Nicola L, Conte G: Renal hemodynamic response to maximal vasodilating stimulus in healthy older subjects. Kidney Int 59: 1052-1058, 2001
18. Berg UB: Differences in decline in GFR with age between males and females: Reference data on clearances of inulin and PAH in potential kidney donors. Nephrol Dial Transplant 21: 2577-2582, 2006
19. Cusack BJ: Pharmacokinetics in older persons. Am J Geriatr Pharmacother 2: 274-302, 2004
20. Zhou XJ, Saxena R, Liu Z, Vaziri ND, Silva FG: Renal senescence in 2008: Progress and challenges. Int Urol Nephrol 40: 823-839, 2008
21. Esposito C, Plati A, Mazzullo T, Fasoli G, De Mauri A, Grosjean F, Mangione F, Castoldi F, Serpieri N, Cornacchia F, Dal Canton A: Renal function and functional reserve in healthy elderly individuals. J Nephrol 20: 617-625, 2007
22. Wetzels JF, Kiemeney LA, Swinkels DW, Willems HL, den Heijer M: Age- and gender-specific reference values of estimated GFR in Caucasians: The Nijmegen Biomedical Study. Kidney Int 72: 632-637, 2007
23. Fehrman-Ekholm I, Skeppholm L: Renal function in the elderly (>70 years old) measured by means of iohexol clearance, serum creatinine, serum urea and estimated clearance. Scand J Urol Nephrol 38: 73-77, 2004
24. Lindeman RD, Tobin J, Shock NW: Longitudinal studies on the rate of decline in renal function with age. J Am Geriatr Soc 33: 278-285, 1985
25. Burkhardt H, Bojarsky G, Gretz N, Gladisch R: Creatinine clearance, Cockcroft-Gault formula and cystatin C: estimators of true glomerular filtration rate in the elderly? Gerontology 48: 140-146, 2002
26. Gill J, Malyuk R, Djurdjev O, Levin A: Use of GFR equations to adjust drug doses in an elderly multi-ethnic group: A cautionary tale. Nephrol Dial Transplant 22: 2894-2899, 2007
27. Stevens LA, Coresh J, Feldman HI, Greene T, Lash JP, Nelson RG, Rahman M, Deysher AE, Zhang YL, Schmid CH, Levey AS: Evaluation of the modification of diet in renal disease study equation in a large diverse population. J Am Soc Nephrol 18: 2749-2757, 2007
28. Shlipak MG: Cystatin C as a marker of glomerular filtration rate in chronic kidney disease: Influence of body composition. Nat Clin Pract Nephrol 3: 188-189, 2007
29. Tidman M, Sjö ström P, Jones I: A Comparison of GFR estimating formulae based upon s-cystatin C and s-creatinine and a combination of the two. Nephrol Dial Transplant 23: 154-160, 2008
30. Spruill WJ, Wade WE, Cobb HH 3rd: Comparison of estimated glomerular filtration rate with estimated creatinine clearance in the dosing of drugs requiring adjustments in elderly patients with declining renal function. Am J Geriatr Pharmacother 6: 153-160, 2008
31. Han PY, Duffull SB, Kirkpatrick CM, Green B: Dosing in obesity: A simple solution to a big problem. Clin Pharmacol Ther 82: 505-508, 2007
32. Coresh J, Astor B: Decreased kidney function in the elderly: Clinical and preclinical, neither benign. Ann Intern Med 145: 299-301, 2006
33. Nolin TD, Frye RF, Matzke GR: Hepatic drug metabolism and transport in patients with kidney disease. Am J Kidney Dis 42: 906-925, 2003
34. Takamura N, Maruyama T, Otagiri M: Effects of uremic toxins and fatty acids on serum protein binding of furosemide: Possible mechanism of the binding defect in uremia. Clin Chem 43: 2274-2280, 1997
35. Benet LZ, Hoener BA: Changes in plasma protein binding have little clinical relevance. Clin Pharmacol Ther 71: 115-121, 2002
36. Cheng JW, Charland SL, Shaw LM, Kobrin S, Goldfarb S, Stanek EJ, Spinler SA: Is the volume of distribution of digoxin reduced in patients with renal dysfunction? Determining digoxin pharmacokinetics by fluorescence polarization immunoassay. Pharmacotherapy 17: 584-590, 1997
37. Keller F, Frankewitsch T, Zellner D, Simon S, Czock D, Giehl M: Standardized structure and modular design of a pharmacokinetic database. Comput Methods Programs Biomed 55: 107-115, 1998
38. Sahin S, Benet LZ: The operational multiple dosing half-life: A key to defining drug accumulation in patients and to designing extended release dosage forms. Pharm Res 25: 2869-2877, 2008
39. Dettli L: Drug dosage in renal disease. Clin Pharmacokinet 1: 126-134, 1976
40. Levy R, Ragueneau-Majlessi I, Solanki B, Zannikos P, Yao C, Novak G: Pharmacokinetics, safety, and tolerability of the new antiepileptic carisbamate in the elderly. Epilepsy Res 79: 22-30, 2008
41. Ahn JE, Cloyd JC, Brundage RC, Marino SE, Conway JM, Ramsay RE, White JR, Musib LC, Rarick JO, Birnbaum AK, Leppik IE: Phenytoin half-life and clearance during maintenance therapy in adults and elderly patients with epilepsy. Neurology 71: 38-43, 2008
42. Perucca E: Age-related changes in pharmacokinetics: Predictability and assessment methods. Int Rev Neurobiol 81: 183-199, 2007
43. Pai MP, Bearden DT: Antimicrobial dosing considerations in obese adult patients. Pharmacotherapy 27: 1081-1091, 2007
44. Noreddin AM, Haynes V: Use of pharmacodynamic principles to optimise dosage regimens for antibacterial agents in the elderly. Drugs Aging 24: 275-292, 2007
45. Butler JM, Begg EJ: Free drug metabolic clearance in elderly people. Clin Pharmacokinet 47: 297-321, 2008
46. Kunin CM: A guide to use of antibiotics in patients with renal disease: A table of recommended doses and factors governing serum levels. Ann Intern Med 67: 151-158, 1967
47. Fliser D, Bischoff I, Hanses A, Block S, Joest M, Ritz E, Mutschler E: Renal handling of drugs in the healthy elderly: Creatinine clearance underestimates renal function and pharmacokinetics remain virtually unchanged. Eur J Clin Pharmacol 55: 205-211, 1999
48. Mallet L, Spinewine A, Huang A: The challenge of managing drug interactions in elderly people. Lancet 370: 185-191, 2007
49. Sonck J, Laureys G, Verbeelen D: The neurotoxicity and safety of treatment with cefepime in patients with renal failure. Nephrol Dial Transplant 23: 966-970, 2008
50. Mahe I, Gouin-Thibault I, Drouet L, Simoneau G, Di Castillo H, Siguret V, Bergmann JF, Pautas E: Elderly medical patients treated with prophylactic dosages of enoxaparin: Influence of renal function on anti-Xa activity level. Drugs Aging 24: 63-71, 2007
51. Eyer F, Pfab R, Felgenhauer N, Lutz J, Heemann U, Steimer W, Zondler S, Fichtl B, Zilker T: Lithium poisoning: Pharmacokinetics and clearance during different therapeutic measures. J Clin Psychopharmacol 26: 325-330, 2006
52. Asche CV, McAdam-Marx C, Shane-McWhorter L, Sheng X, Plauschinat CA: Evaluation of adverse events of oral antihyperglycemic monotherapy experienced by a geriatric population in a real-world setting: A retrospective cohort analysis. Drugs Aging 25: 611-622, 2008
53. Almirall J, Bricullé M, Gonzalez-Clemente JM: Metformin-associated lactic acidosis in type 2 diabetes mellitus: Incidence and presentation in common clinical practice. Nephrol Dial Transplant 23: 2436-2438, 2008
54. Karie S, Gandjbakhch F, Janus N, Launay-Vacher V, Rozenberg S, Mai Ba CU, Bourgeois P, Deray G: Kidney disease in RA patients: Prevalence and implication on RA-related drugs management - The MATRIX study. Rheumatology (Oxford) 47: 350-354, 2008
55. Bernatsky S, Ehrmann Feldman D: Discontinuation of methotrexate therapy in older patients with newly diagnosed rheumatoid arthritis: Analysis of administrative health databases in Québec, Canada. Drugs Aging 25: 879-884, 2008
56. Czock D, Keller F: Mechanism-based pharmacokinetic-pharmacodynamic modeling of antimicrobial drug effects. J Pharmacokinet Pharmacodyn 34: 727-751, 2007
57. Czock D, Giehl M: Aminoglycoside pharmacokinetics and-dynamics: A nonlinear approach. Int J Clin Pharmacol Ther 33: 537-539, 1995
58. Krzyzanski W, Jusko WJ: Integrated functions for four basic models of indirect pharmacodynamic response. J Pharm Sci 87: 67-72, 1998
59. Czock D, Giehl M, Keller F: A concept for pharmacokinetic-pharmacodynamic dosage adjustment in renal impairment: The case of aminoglycosides [published erratum appears in Clin Pharmacokinet 39: 231, 2000]. Clin Pharmacokinet 38: 367-375, 2000
60. Keller F, Aymanns C, Czock D: Pharmacokinetics. In: Encyclopedia of Molecular Pharmacology, 2nd Ed., Vol. 1 A-L, edited by Offermanns S, Rosenthal W, Berlin, Springer, 2008, pp 954-960
61. Field TS, Gurwitz JH, Harrold LR, Rothschild J, DeBellis KR, Seger AC, Auger JC, Garber LA, Cadoret C, Fish LS, Garber LD, Kelleher M, Bates DW: Risk factors for adverse drug events among older adults in the ambulatory setting. J Am Geriatr Soc 52: 1349-1354, 2004
62. Delafuente JC: Pharmacokinetic and pharmacodynamic alterations in the geriatric patient. Consult Pharm 23: 324-334, 2008
63. Faught E: Monotherapy in adults and elderly persons. Neurology 69[Suppl 3]: S3-S9, 2007
64. ElDesoky ES: Pharmacokinetic-pharmacodynamic crisis in the elderly. Am J Ther 14: 488-498, 2007
65. Blumstein H, Gorevic PD: Rheumatologic illnesses: Treatment strategies for older adults. Geriatrics 60: 28-35, 2005
66. Abernethy DR: Aging effects on drug disposition and effect. Geriatr Nephrol Urol 9: 15-19, 1999
67. Catterson ML, Preskorn SH, Martin RL: Pharmacodynamic and pharmacokinetic considerations in geriatric psychopharmacology. Psychiatr Clin North Am 20: 205-218, 1997
68. Harashima S, Kondo H, Nabeshima A, Shimoda M, Yamaji K, Horiuchi T, Shimono N, Ikematsu H: The relationship between the daily dosage of the carbapenem meropenem (MEPM) and MEPM-resistant Pseudomonas aeruginosa. J Infect Chemother 14: 219-222, 2008
69. Sandiumenge A, Diaz E, Bodí M, Rello J: Therapy of ventilator-associated pneumonia: A patient-based approach based on the ten rules of "The Tarragona Strategy." Intensive Care Med 29: 876-883, 2003
70. Löwenberg B, Ossenkoppele GJ, van Putten W, Schouten HC, Graux C, Ferrant A, Sonneveld P, Maertens J, Jongen-Lavrencic M, von Lilienfeld-Toal M, Biemond BJ, Vellenga E, van Marwijk Kooy M, Verdonck LF, Beck J, Döhner H, Gratwohl A, Pabst T, Verhoef G, Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON), German AML Study Group (AMLSG), Swiss Group for Clinical Cancer Research (SAKK) Collaborative Group: High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med 361: 1235-1248, 2009
71. Wildiers H, Highley MS, de Bruijn EA, van Oosterom AT: Pharmacology of anticancer drugs in the elderly population. Clin Pharmacokinet 42: 1213-1242, 2003
72. Wildiers H, Paridaens R: Taxanes in elderly breast cancer patients. Cancer Treat Rev 30: 333-342, 2004
73. Skirvin JA, Lichtman SM: Pharmacokinetic considerations of oral chemotherapy in elderly patients with cancer. Drugs Aging 19: 25-42, 2002
74. Swift CG, Homeida M, Halliwell M, Roberts CJ: Antipyrine disposition and liver size in the elderly. Eur J Clin Pharmacol 14: 149-152, 1978
75. Punyawudho B, Ramsay RE, Macias FM, Rowan AJ, Collins JF, Brundage RC, Birnbaum AK: Population pharmacokinetics of lamotrigine in elderly patients. J Clin Pharmacol 48: 455-463, 2008
76. He YL, Sabo R, Campestrini J, Wang Y, Riviere GJ, Nielsen JC, Rosenberg M, Ligueros-Saylan M, Howard D, Dole WP: The effect of age, gender, and body mass index on the pharmacokinetics and pharmacodynamics of vildagliptin in healthy volunteers. Br J Clin Pharmacol 65: 338-346, 2008
77. Wyatt CM, Kim MC, Winston JA: Therapy insight: How changes in renal function with increasing age affect cardiovascular drug prescribing. Nat Clin Pract Cardiovasc Med 3: 102-109, 2006
78. Chien SC, Chow AT, Natarajan J, Williams RR, Wong FA, Rogge MC, Nayak RK: Absence of age and gender effects on the pharmacokinetics of a single 500-milligram oral dose of levofloxacin in healthy subjects. Antimicrob Agents Chemother 41: 1562-1565, 1997
79. Liukas A, Kuusniemi K, Aantaa R, Virolainen P, Neuvonen M, Neuvonen P, Olkkola K: Plasma concentrations of oral oxycodone are greatly increased in the elderly. Clin Pharmacol Ther 84: 462-467, 2008
80. Urien S, Laurent N, Barre J, Druguet M, Bouvier D'yvoire M, Maire P: Pharmacokinetic modelling of cefotaxime and desacetylcefotaxime: A population study in 25 elderly patients. Eur J Clin Pharmacol 60: 11-16, 2004
81. Dilger K, Herrlinger C, Peters J, Seyberth HW, Schweer H, Klotz U: Effects of celecoxib and diclofenac on blood pressure, renal function, and vasoactive prostanoids in young and elderly subjects. J Clin Pharmacol 42: 985-994, 2002
82. Linnebur SA, Milchak JL: Assessment of oral bisphosphonate use in elderly patients with varying degrees of kidney function. Am J Geriatr Pharmacother 2: 213-218, 2004
83. Cancelli I, Gigli GL, Piani A, Zanchettin B, Janes F, Rinaldi A, Valente M: Drugs with anticholinergic properties as a risk factor for cognitive impairment in elderly people: A population-based study. J Clin Psychopharmacol 28: 654-659, 2008
84. Cancelli I, Valentinis L, Merlino G, Valente M, Gigli GL: Drugs with anticholinergic properties as a risk factor for psychosis in patients affected by Alzheimer's disease. Clin Pharmacol Ther 84: 63-68, 2008
85. Bowie MW, Slattum PW: Pharmacodynamics in older adults: A review. Am J Geriatr Pharmacother 5: 263-303, 2007
86. Wilder-Smith OH: Opioid use in the elderly. Eur J Pain 9: 137-140, 2005
87. Raje S, Patat AA, Parks V, Schechter L, Plotka A, Paul J, Langstrom B: A positron emission tomography study to assess binding of lecozotan, a novel 5-hydroxytryptamine-1A silent antagonist, to brain 5-HT1A receptors in healthy young and elderly subjects, and in patients with Alzheimer's disease. Clin Pharmacol Ther 83: 86-96, 2008
88. Platten HP, Schweizer E, Dilger K, Mikus G, Klotz U: Pharmacokinetics and the pharmacodynamic action of midazolam in young and elderly patients undergoing tooth extraction. Clin Pharmacol Ther 63: 552-560, 1998
89. de Almeida MC, Latorre F, Gervais HW, Kleeman PP: The effects of age on onset and recovery from atracurium, rocuronium and vecuronium blockade [in German]. Anaesthesist 45: 903-906, 1996
90. LeBlanc JM, Dasta JF, Pruchnicki MC, Schentag JJ: Impact of disease states on the pharmacokinetics and pharmacodynamics of angiotensin-converting enzyme inhibitors. J Clin Pharmacol 46: 968-980, 2006
91. Adembri C, Novelli A: Pharmacokinetic and pharmacodynamic parameters of antimicrobials: potential for providing dosing regimens that are less vulnerable to resistance. Clin Pharmacokinet 48: 517-528, 2009